Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver.

Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver.
复制标题

DOI:
10.1002/hep.27104
复制
发表时间:
2014-09
期刊:
影响因子:
13.5
通讯作者:
Thoeny, Beat
Thoeny, Beat
中科院分区:
医学1区
文献类型:
--
作者:
Viecelli, Hiu Man;Harbottle, Richard P.;Wong, Suet Ping;Schlegel, Andrea;Chuah, Marinee K.;VandenDriessche, Thierry;Harding, Cary O.;Thoeny, Beat

文献摘要

参考文献

相似文献

Host immune response to viral vectors, persistence of nonintegrating vectors, and sustained transgene expression are among the major challenges in gene therapy. To overcome these hurdles, we successfully used minicircle (MC) naked-DNA vectors devoid of any viral or bacterial sequences for the long-term treatment of murine phenylketonuria, a model for a genetic liver defect. MC-DNA vectors expressed the murine phenylalanine hydroxylase (Pah) complementary DNA (cDNA) from a liver-specific promoter coupled to a de novo designed hepatocyte-specific regulatory element, designated P3, which is a cluster of evolutionary conserved transcription factor binding sites. MC-DNA vectors were subsequently delivered to the liver by a single hydrodynamic tail vein (HTV) injection. The MC-DNA vector normalized blood phenylalanine concomitant with reversion of hypopigmentation in a dose-dependent manner for more than 1 year, whereas the corresponding parental plasmid did not result in any phenylalanine clearance. MC vectors persisted in an episomal state in the liver consistent with sustained transgene expression and hepatic PAH enzyme activity without any apparent adverse effects. Moreover, 14–20% of all hepatocytes expressed transgenic PAH, and the expression was observed exclusively in the liver and predominately around pericentral areas of the hepatic lobule, while there was no transgene expression in periportal areas. This study demonstrates that MC technology offers an improved safety profile and has the potential for the genetic treatment of liver diseases.
DOI: 10.1074/jbc.m303986200
发表时间: 2003-07-25
影响因子: 4.8
作者:
Elzaouk, L;Leimbacher, W;Thöny, B
通讯作者: Thöny, B
DOI: 10.1038/mt.2008.294
发表时间: 2009-03-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Kamimura, Kenya;Suda, Takeshi;Liu, Dexi
通讯作者: Liu, Dexi
DOI: 10.1038/sj.mt.6300399
发表时间: 2008-03-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Chen, Zhi-Ying;Riu, Efren;Kay, Mark A.
通讯作者: Kay, Mark A.
DOI: 10.1016/j.ymgme.2011.12.025
发表时间: 2012-04-01
影响因子: 3.8
作者:
Heintz, Caroline;Troxler, Heinz;Blau, Nenad
通讯作者: Blau, Nenad
DOI: 10.1016/j.ymthe.2005.03.025
发表时间: 2005-08-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Hamman, K;Clark, H;Harding, CO
通讯作者: Harding, CO